AstraZeneca PLC logged a -2.4% change during today's morning session, and is now trading at a price of $69.45 per share. The ...

The Cambridge, England-based pharmaceutical company said Imfinzi has been approved in the EU for treatments in adults with resectable muscle-invasive bladder cancer. The approval is for the use of ...

US President Donald Trump said he plans to start sending letters informing trading partners of their tariff rates.

ASTRAZENECA is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with ...

AstraZeneca PLC closed 22.80% short of its 52-week high of £133.88, which the company reached on September 3rd.

By integrating foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods.

The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.

AstraZeneca AZN announced that the European Commission has approved its blockbuster cancer drug, Imfinzi (durvalumab), for a ...

The country's premier medical institution said that its studies have found no connection between Covid jabs and sudden deaths ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

UK pharma major AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal ...

The FTSE 100 and European stocks were jittery on Friday, moving lower while US markets were closed for 4 July, as investors ...